- ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003‑P) in Participants with Tuberous Sclerosis Complex (1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) who Experience Inadequately‑controlled Seizures
This study looks at a medicine called Epidyolex for young children with Dravet Syndrome, Tuberous Sclerosis Complex, or Lennox-Gastaut Syndrome. It checks if the medicine is safe, how much stays in the body, and if it helps reduce seizures. This is a big final-stage study.
Italy · Spain - authorisedTherapeutic confirmatory (Phase III)
Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome
This study is testing a new medicine, Clemizole HCl, to see if it helps people with a severe type of epilepsy called Lennox-Gastaut Syndrome. Researchers want to know if it can reduce seizures when added to a person's current treatment.
Italy · Spain · Hungary - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Prospective, Interventional, Open-Label, Multisite, Extension Study to Assess the Long-Term Safety and Tolerability of Soticlestat (TAK-935) as Adjunctive Therapy in Subjects with Developmental Epileptic Encephalopathies Including Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome (ENDYMION 1)
Spain · Portugal · Poland